eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2024
vol. 28
 
Share:
Send email
Share:
Original paper

Combination of modified FOLFIRINOX with stereotactic body radiotherapy as an induction therapy for locally advanced pancreatic adenocarcinoma – a prospective single-arm study

Michał Piątek
1, 2
,
Michał Bieńkowski
3
,
Katarzyna Kuśnierz
4
,
Joanna Pilch-Kowalczyk
5
,
Dorota Imielska-Zdunek
6
,
Sławomir Mrowiec
4
,
Paweł Lampe
4
,
Barbara Radecka
2
,
Sergiusz Nawrocki
7, 8

1.
Department of Oncology, Medical University of Silesia, Katowice, Poland
2.
Department of Oncology, Institute of Medical Sciences, University of Opole, Opole, Poland
3.
Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland
4.
Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland
5.
Department of Radiology and Nuclear Medicine, Medical University of Silesia, Katowice, Poland
6.
Radiotherapy Division, prof. K. Gibiński Memorial University Clinical Centre, Silesian Medical University, Katowice, Poland
7.
Department of Radiotherapy, Medical University of Silesia, Katowice, Poland
8.
Oncology Department, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland
Contemp Oncol (Pozn) 2024; 28 (1): 15–30
DOI: https://doi.org/10.5114/wo.2024.137760
Online publish date: 2024/03/28
Article file
- Combination of modified (1).pdf  [1.52 MB]
Get citation
 
PlumX metrics:
 
1. Carioli G, Malvezzi M, Bertuccio P, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Ann Oncol 2021; 32: 478-487.
2. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics. Cancer J Clin 2021; 71: 7-33.
3. NCCN, Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma version 2.2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf (accessed: 09.10.2023).
4. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046.
5. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
6. Katz MHG, Marsh R, JHerman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013; 20: 2787-2795.
7. Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg Oncol 2019; 270: 340.
8. Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med 2019; 19: 149-157.
9. Jung JH, Song C, Jung IH, et al. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. Front Oncol 2022; 12: 1050070.
10. Janssen QP, van Dam JL, Doppenberg D, et al. FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium. JNCI 2022; 114: 695-703.
11. Suker M, Nuyttens JJ, Eskens FALM, et al. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). EClinicalMedicine 2019; 17: 100200.
12. Eshmuminov D, Aminjonov B, Palm RF, et al. FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Ann Surg Oncol 2023; 30: 4417-4428.
13. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55.
14. Tchelebi LT, Lehrer EJ, Trifiletti DM, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis. Cancer 2020; 126: 2120-2131.
15. Dohopolski MJ, Glaser SM, Vargo JA, Balasubramani GK, Beriwal S. Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer – patterns of care and overall survival. J Gastrointest Oncol 2017; 8: 766.
16. Chuong M, Lee P, Low D, et al. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study. Radiother Oncol 2024; 191: 110064.
17. Massaccesi M, Cusumano D, Boldrini L, et al. A new frontier of image guidance: organs at risk avoidance with MRI-guided respiratory-gated intensity modulated radiotherapy: technical note and report of a case. J Appl Clin Med Phys 2019; 20: 194-198.
18. Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi- institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015; 121: 1128-1137.
19. Hill CS, Rosati L, Wang H, et al. Multiagent chemotherapy and stereotactic body radiation therapy in patients with unresectable pancreatic adenocarcinoma: a prospective nonrandomized controlled trial. Pract Radiat Oncol 2022; 12: 511-523.
20. Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J Clin Oncol 2021; 39: 377-377.
21. Ghorani E, Wong HH, Hewitt C, Calder J, Corrie P, Basu B. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience. Oncology 2015; 89: 281-287.
22. Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep 2018; 8: 8666.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (ver- sion 1.1). Eur J Cancer 2009; 45: 228-247.
24. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality- of-life instrument for use in international clinical trials in oncology. JNCI 1993; 85: 365-376.
25. Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur J Cancer 1999; 35: 939-941.
26. EORTC, Common Terminology Criteria for Adverse Events (CTCAE). Available from: https://www.eortc.be/services/doc/ctc/ctcae_4.03_ 2010-06-14_quickreference_5x7.pdf. (accessed: 09.10.2023).
27. R Core Team. R: a language and environment for statistical computing. Available from: https://www.scirp.org/reference/ReferencesPapers?ReferenceID=1787696.
28. Seshan VE. Clinfun: clinical trial design and data analysis functions. R package version 2018; 1.
29. Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol 2018; 44: 1619-1623.
30. Van Veldhuisen E, van den Oord C, Brada LJ, et al. Locally advanced pancreatic cancer: work-up, staging, and local intervention strategies. Cancers 2019; 11: 976.
31. Morak MJM, Richel DJ, van Eijck CHJ, et al. Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Radiother Oncol 2011; 98: 261-264.
32. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed- effects models using lme4. J Stat Softw 2015; 67: 1-48.
33. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Statistic Software 2017; 82: 1-26.
34. Wickham H. ggplot2: elegant graphics for data analysis. Springer- Verlag, New York 2009.
35. Kassambara A, Kosinski M, Biecek P, Fabian S. Survminer: drawing survival curves using ‘ggplot2. R package version 0.3 2017; 1.
36. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Network Open 2021; 4: e214708-e214708.
37. Teriaca MA, Loi M, Suker M, Eskens FALM, van Eijck CHJ, Nuyttens JJ. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): long-term outcome. Radiother Oncol 2021; 155: 232-236.
38. Reyngold M, O’Reilly EM, Varghese AM, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol 2021; 7: 735-738.
39. Chang D. Phase III FOLFIRINOX (mFFX) +/– SBRT in locally advanced pancreatic cancer (NCT01926197). Available from: https://clinicaltrials.gov/ct2/show/NCT01926197 (accessed: 09.10.2023).
40. Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6: 128-138.
41. Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. J Clin Oncol 2022; 40: 4008-4008.
42. Yoo C. mFOLFIRINOX with or without stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma (SABER) (NCT04986930). Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04986930 (accessed: 04.03.2024).
43. Chen I. Nivolumab, ipilimumab and chemoradiation in pancreatic cancer. (LAPTOP) (NCT04247165). Available from: https://clinicaltrials.gov/study/NCT04247165 (accessed: 04.03.2024).
44. Oar A. MFOLFIRINOX and stereotactic radiotherapy (SBRT) for pancreatic cancer with high risk and locally advanced disease (MASTERPLAN) (NCT04089150). Available from: https://clinicaltrials.gov/study/NCT04089150 (accessed: 04.03.2024].
45. Dunlap N. Effects of folfirinox and stereotactic body radiation therapy for advanced pancreatic cancer (BCC-RAD-13) (NCT02128100). Available from: https://clinicaltrials.gov/study/NCT02128100 (accessed: 04.03.2024).
46. Kim H. Stereotactic body radiotherapy and focal adhesion kinase inhibitor in advanced pancreas adenocarcinoma (NCT04331041). Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04331041 (accessed: 04.03.2024).
47. Portalès F. Sequential treatment with GEMBRAX and then FOLFIRINOX followed by stereotactic MRI-guided radiotherapy in patients with locally advanced pancreatic cancer (GABRINOX-ART) (NCT04570943). Available from: https://www.clinicaltrials.gov/study/NCT04570943 (accessed: 04.03.2024).
48. Therapeutics G. Phase 2b study of GC4711 in combination with SBRT for nonmetastatic pancreatic cancer (NCT04698915). Available from: https://clinicaltrials.gov/study/NCT04698915 (accessed: 04.03.2024).
49. Viewray Inc. Locally advanced pancreatic cancer treated with ABLAtivE stereotactic MRI-guided adaptive radiation therapy (LAP-ABLATE) (NCT05585554). Available from: https://clinicaltrials.gov/study/NCT05585554 (accessed: 04.03.2024).
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.